Fidelity Select Pharmaceuticals Port holds a quantitatively derived Gold Morningstar Medalist Rating. The rating reflects that it has scored particularly well on factors Morningstar research associates with future outperformance relative to category peers.
Fidelity Select Pharmaceuticals Portfolio FPHAX
- NAV / 1-Day Return 33.22 / −0.78 %
- Total Assets 1.5B
-
Adj. Expense Ratio
0.670%
- Expense Ratio 0.670%
- Distribution Fee Level Low
- Share Class Type No Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 2.66%
- Turnover 77%
USD | NAV as of Jun 06, 2026 | 1-Day Return as of Jun 06, 2026, 4:50 AM GMT+0
Morningstar’s Analysis FPHAX
Will FPHAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the FPHAX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of FPHAX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 74.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 26.23 | 365M | Healthcare |
GSK PLC ADR | 9.16 | 128M | Healthcare |
Johnson & Johnson | 6.08 | 85M | Healthcare |
Viatris Inc | 5.40 | 75M | Healthcare |
UCB SA | 4.84 | 67M | Healthcare |
Roche Holding AG Ordinary Shares new | 4.76 | 66M | Healthcare |
Merck & Co Inc | 4.70 | 65M | Healthcare |
AstraZeneca PLC | 4.62 | 64M | Healthcare |
Legend Biotech Corp ADR | 4.26 | 59M | Healthcare |
Gilead Sciences Inc | 4.21 | 59M | Healthcare |
United States